A Pragmatic Randomized Clinical Trial of Early Dronedarone
Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation
A Common Problem
Atrial Fibrillation (AFib) is an irregular heartbeat, and it is the most common arrhythmia seen in clinical practice. Anyone can develop AFib. It can lead to heart complications and increases the risk of having a stroke by five times.
Millions of Americans have AFib, and that number continues to rise. It is estimated that by 2030 AFib will affect 12.1 million people in the United States, which is more than double the number in 2010.
First Pragmatic Trial
Establishing treatment options for newly diagnosed patients is an integral part of a care plan to help patients live longer, healthier lives. This is the first pragmatic trial to focus on identifying treatment best practices for first-detected AFib. This trial is a collaboration between the American Heart Association®, the world’s leading nonprofit organization focused on heart and brain health, and the Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization, with support from Sanofi US.
Become a Part of the Trial
Launched in late 2021 and concluding in 2024, CHANGE AFib seeks to determine if early treatment with the antiarrhythmic drug dronedarone improves cardiovascular outcomes and quality of life in patients presenting to the hospital with first detected AFib.
Hospitals and providers involved in the diagnosis, treatment, and management of AFib patients are encouraged to learn more about how to participate.
* This is an estimate of the number of people in the United States who currently have AFib.